Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
Current Oncology · 2023
DOI: 10.3390/curroncol30060433 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, 2023. Verfasst von Ezra Hahn und 6 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada. Hauptthemen laut MEDLINE: Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing treatment approach in order to reduce the risk of local recurrence (LR), including invasive LR, which carries a subsequent risk of breast cancer mortality. However, reliable and accurate individual risk prediction remains elusive and RT continues to be standardly recommended for most women with DCIS. Three molecular biomarkers have been studied to better estimate LR risk after BCS—Oncotype DX DCIS score, DCISionRT Decision Score and its associated Residual Risk subtypes, and Oncotype 21-gene Recurrence Score. All these molecular biomarkers represent important efforts towards improving predicted risk of LR after BCS. To prove clinical utility, these biomarkers require careful predictive modeling with calibration and external validation, and evidence of benefit to patients; on this front, further research is needed. Most trials do not incorporate molecular biomarkers in evaluating de-escalation of therapy for DCIS; however, one—the Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk DCIS (ELISA) trial—incorporates the Oncotype DX DCIS score in defining a low-risk population and is an important next step in this line of research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada.
- Department of Radiation Oncology, University of Toronto, Toronto, ON M5T 1P5, Canada.
- Institute for Clinical Evaluative Sciences, Toronto, ON M4N 3M5, Canada.
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
ORCID-Profile: Danielle Rodin, Eileen Rakovitch
Zitieren
APA
Hahn, E., Rodin, D., Sutradhar, R., Nofech-Mozes, S., Trebinjac, S., Paszat, L. F., & Rakovitch, E. (2023). Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?. Current Oncology. https://doi.org/10.3390/curroncol30060433
Vancouver
Hahn E, Rodin D, Sutradhar R, Nofech-Mozes S, Trebinjac S, Paszat LF, et al. Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?. Current Oncology. 2023. doi:10.3390/curroncol30060433
BibTeX
@article{Hahn2023,
author = {Hahn, Ezra and Rodin, Danielle and Sutradhar, Rinku and Nofech-Mozes, Sharon and Trebinjac, Sabina and Paszat, Lawrence Frank and Rakovitch, Eileen},
title = {Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30060433}
}
EUVIMED